RAPT Therapeutics RAPT 深 沪
等待开盘 12-16 09:30:00 美东时间
33.215
-3.585
-9.74%
华盛通- 最 高37.385
- 今 开36.83
- 成交量 38.47万股
- 最 低 32.98
- 昨 收 36.80
- 总市值 9.20亿
- 52周最高 42.3918
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.6656
- 委 比 66.67%
- 总股本 2771.09万
- 历史最高 409.68
- 量 比 1.00
- 振 幅 11.97%
- 历史最低 5.6656
- 每 手 1
- 风险率 8.85%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多RAPT Therapeutics Announces CMO Departure
RAPT Therapeutics ( ($RAPT) ) has issued an update. On November 24, 2025, RAPT ...
11-29 03:28
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Barclays Maintains Overweight on RAPT Therapeutics, Lowers Price Target to $56
Barclays analyst Etzer Darout maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and lowers the price target from $58 to $56.
11-07 23:49
RAPT Therapeutics Q3 EPS $(0.65) Beats $(0.80) Estimate
RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.80) by 19.15 percent. This is a 82.85 percent increase over losses of $(3.79) per share from
11-06 21:30
RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
RAPT Therapeutics reported positive Phase 2 results for ozureprubart in chronic spontaneous urticaria, showing comparable efficacy and safety to omalizumab. The company also initiated a Phase 2b trial for food allergy and completed a $250M public offering to strengthen its balance sheet. Net loss for Q3 2025 was $17.6M, with R&D expenses down 10% year-over-year and G&A expenses up 14%. Cash and marketable securities totaled $157.3M as of Septembe...
11-06 13:00
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
RAPT Therapeutics, a clinical-stage biopharmaceutical company focused on therapies for inflammatory and immunological diseases, announced that its management team will participate in three investor conferences in November 2025: Guggenheim's 2nd Annual Healthcare Innovation Conference on November 11, Stifel 2025 Healthcare Conference on November 12, and TD Cowen Virtual Immunology & Inflammation Summit on November 13. Details and recordings can be...
11-04 21:05
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
HC Wainwright & Co. Maintains Buy on RAPT Therapeutics, Raises Price Target to $72
HC Wainwright & Co. analyst Emily Bodnar maintains RAPT Therapeutics (NASDAQ:RAPT) with a Buy and raises the price target from $27 to $72.
10-28 00:57
